Immunovant Inc (IMVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
Immunovant Inc (IMVT) Competitors
The companies most similar to Immunovant are Immunitybio (IBRX), Abivax SA American Depositary Shares (ABVX) and TG Therapeutics (TGTX). By market cap, Immunovant ranks 7th of the 13 companies on this page; Vaxcyte (PCVX) is the largest at $10.03B.
Peer Comparison
IMVT's revenue growth of 0.0% is below the peer median of 57.8%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Immunovant (IMVT) | $7.07B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immunitybio Inc (IBRX) | $6.40B | N/A | 30.3x | 0.0% | -780.5% | 52.3% | 0.00% |
| Abivax SA American Depositary Shares (ABVX) | $7.67B | N/A | N/A | 0.0% | -159.6% | -6.8% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| Iovance Biotherapeutics Inc (IOVA) | $3.59B | N/A | 9.1x | -58.2% | N/A | 80.1% | 0.00% |
| Vaxcyte Inc (PCVX) | $10.03B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Dianthus Therapeutics Inc. (DNTH) | $5.17B | N/A | N/A | 0.0% | N/A | 205.6% | 0.00% |
| Protagonist Therapeutics Inc (PTGX) | $8.55B | 27.7x | 15.8x | 62.0% | N/A | 5724.0% | 0.00% |
| CG Oncology, Inc. Common stock (CGON) | $6.65B | N/A | N/A | 0.0% | -21.1% | -3.7% | 0.00% |
| Ionis Pharmaceuticals Inc (IONS) | $4.84B | N/A | 4.8x | -56.9% | -29.3% | 54.9% | 0.00% |
| Mirum Pharmaceuticals Inc (MIRM) | $6.14B | N/A | 8.9x | -134.7% | -133.6% | 39.6% | 0.00% |
| Praxis Precision Medicines Inc (PRAX) | $9.17B | N/A | N/A | 0.0% | N/A | 1349.0% | 0.00% |
| Cytokinetics Inc (CYTK) | $7.82B | N/A | 65.3x | 0.0% | -66.0% | 2357.0% | 0.00% |
| Peer median | $7.16B | 57.5x | 11.1x | 0.0% | -66.0% | 57.8% | 0.00% |
Similar Companies
These are the 12 companies most similar to Immunovant, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Immunitybio Inc (IBRX) | ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose... | IBRX competitors |
| Abivax SA American Depositary Shares (ABVX) | Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. | ABVX competitors |
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| Iovance Biotherapeutics Inc (IOVA) | Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness... | IOVA competitors |
| Vaxcyte Inc (PCVX) | Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. | PCVX competitors |
| Dianthus Therapeutics Inc. (DNTH) | Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops... | DNTH competitors |
| Protagonist Therapeutics Inc (PTGX) | Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical... | PTGX competitors |
| CG Oncology, Inc. Common stock (CGON) | CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070... | CGON competitors |
| Ionis Pharmaceuticals Inc (IONS) | Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California. | IONS competitors |
| Mirum Pharmaceuticals Inc (MIRM) | Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies... | MIRM competitors |
| Praxis Precision Medicines Inc (PRAX) | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal... | PRAX competitors |
| Cytokinetics Inc (CYTK) | Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering... | CYTK competitors |
Frequently Asked Questions About IMVT
Who are Immunovant's main competitors?
The companies most similar to Immunovant include Immunitybio (IBRX), Abivax SA American Depositary Shares (ABVX), TG Therapeutics (TGTX), Iovance Biotherapeutics (IOVA) and Vaxcyte (PCVX), listed from the closest match.
Who is Immunovant's biggest competitor?
Vaxcyte (PCVX) is the largest of the similar companies at $10.03B; Immunitybio (IBRX) is the closest match by business profile, size, sector and industry.
How does IMVT stock compare with its competitors?
IMVT's net margin is 0.0% against a peer median of 0.0%.
Which of Immunovant's competitors pays a higher dividend?
Immunovant pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Immunovant bigger than its competitors?
No. Immunovant is 7th by market cap among the 13 companies on this page; the largest is Vaxcyte (PCVX) at $10.03B.
IMVT pages: Overview, Earnings, Forecast, Financials, Competitors